Publicacións nas que colabora con Carlos Montilla Morales (29)

2024

  1. Influence of comorbidities not associated with fibromyalgia on neuropathic pain in patients with psoriatic arthritis: relationship with clinical parameters

    Frontiers in Medicine, Vol. 11

2023

  1. Confounders contributing to explain the association between sex and disease impact in patients with recent-onset psoriatic arthritis

    Clinical and experimental rheumatology, Vol. 41, Núm. 1, pp. 137-144

  2. Expert recommendations for the use of apremilast in psoriatic arthritis

    Reumatologia Clinica, Vol. 19, Núm. 1, pp. 34-44

  3. Implantación de un modelo de aula invertida en la docencia de Reumatología en el Grado de Fisioterapia

    Educación hacia el futuro: enfoque STEAM, ciencias de la salud y deporte (Dykinson), pp. 300-309

  4. Moderate-High Disease Activity in Patients with Recent-Onset Psoriatic Arthritis—Multivariable Prediction Model Based on Machine Learning

    Journal of Clinical Medicine, Vol. 12, Núm. 3

2022

  1. Characteristics associated with the perception of high-impact disease (PsAID ≥4) in patients with recent-onset psoriatic arthritis. Machine learning-based model

    Seminars in Arthritis and Rheumatism, Vol. 57

  2. Minimal disease activity (MDA) in patients with recent-onset psoriatic arthritis: predictive model based on machine learning

    Arthritis research & therapy, Vol. 24, Núm. 1, pp. 153

  3. Severe Disease in Patients With Recent-Onset Psoriatic Arthritis. Prediction Model Based on Machine Learning

    Frontiers in Medicine, Vol. 9

2021

  1. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study

    European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382

2020

  1. Disease features associated with a low disease impact in patients with psoriatic arthritis: Results of a cross-sectional multicenter study

    Arthritis Research and Therapy, Vol. 22, Núm. 1

2019

  1. Correction: Very low disease activity, DAPSA remission, and impact of disease in a Spanish population with psoriatic arthritis (Journal of Rheumatology (2019) 46 (710-715) DOI: 10.3899/jrheum.180460)

    Journal of Rheumatology

  2. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 3, pp. 355-364

  3. Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis 11 Medical and Health Sciences 1117 Public Health and Health Services 11 Medical and Health Sciences 1103 Clinical Sciences

    Arthritis Research and Therapy, Vol. 21, Núm. 1

  4. Spanish Registry of Recent-onset Psoriatic Arthritis (REAPSER study): Aims and methodology

    Reumatologia Clinica, Vol. 15, Núm. 5, pp. 252-257

  5. Very low disease activity, DAPSA remission, and impact of disease in a Spanish population with psoriatic arthritis

    Journal of Rheumatology, Vol. 46, Núm. 7, pp. 710-715

2018

  1. Recommendations for the use of methotrexate in psoriatic arthritis

    Reumatologia Clinica, Vol. 14, Núm. 4, pp. 183-190

  2. Recommendations of the Spanish Society of Rheumatology on treatment and use of systemic biological and non-biological therapies in psoriatic arthritis

    Reumatologia Clinica, Vol. 14, Núm. 5, pp. 254-268

2017

  1. Minimal disease activity and impact of disease in psoriatic arthritis: A Spanish cross-sectional multicenter study

    Arthritis Research and Therapy, Vol. 19, Núm. 1

2016

  1. Association of IL1Β (-511 A/C) and IL6 (-174 G > C) polymorphisms with higher disease activity and clinical pattern of psoriatic arthritis

    Clinical Rheumatology, Vol. 35, Núm. 7, pp. 1789-1794

  2. Etoricoxib in ankylosing spondylitis: Is there a role for active patients refractory to traditional NSAIDs?

    Clinical and Experimental Rheumatology, Vol. 34, Núm. 1, pp. 94-99